Adoptive cell transfer, abbreviated ACT, is the transfer of cells into a patient, most commonly cells derived from the immune system, with the goal of improving immune functionality and characteristics. In autologous cancer immunotherapy, T cells are extracted from the patient, genetically modified and cultured in vitro before being returned to that same patient, while allogeneic therapies instead use cells isolated and expanded from a separate donor.
Facts
Adoptive Cell Transfer
Filter Results5 entries
FAQs
What are the main types of adoptive cell transfer used against cancer?
Tumor-infiltrating lymphocyte therapy and CAR T-cell therapy are the two main types the National Cancer Institute names.
The National Cancer Institute, which calls this approach T-cell transfer therapy, describes it as a type of immunotherapy that makes a patient's own immune cells better able to attack cancer. It names two main types, tumor-infiltrating lymphocyte therapy, often shortened to TIL therapy, and CAR T-cell therapy. This entry records what the source states and is not medical advice.
Connections
Treats
Source Adoptive cell transfer (Wikipedia)
Source Adoptive cell transfer (Wikipedia)
Source Adoptive cell transfer (Wikipedia)
Source Adoptive cell transfer (Wikipedia)
Source Adoptive cell transfer (Wikipedia)
Sources
1. Wikipedia
Wikipedia contributors, Wikimedia Foundation
Adoptive cell transfer (Wikipedia)
https://en.wikipedia.org/wiki/Adoptive_cell_transfer, lead section
Adoptive cell transfer (ACT) is the transfer of cells into a patient.
Treats: Melanoma, Cancer
The adoptive transfer of autologous tumor infiltrating lymphocytes (TIL) or genetically re-directed peripheral blood mononuclear cells has been used experimentally to treat patients with advanced solid tumors, including melanoma and colorectal carcinoma, as well as patients with CD19-expressing hematologic malignancies, cervical cancer, lymphoma, leukemia, bile duct cancer and
Treats: Lymphoma, B cells
For example, the CD19 molecule is expressed on more than 90% of B cell malignancies and on non-plasma B cells at all differentiation stages and has been successfully used to treat patients with follicular lymphoma, large-cell lymphomas, chronic lymphocytic leukemia and acute lymphoblastic leukemia.
Treats: Chronic Lymphocytic Leukemia, B cells
For example, the CD19 molecule is expressed on more than 90% of B cell malignancies and on non-plasma B cells at all differentiation stages and has been successfully used to treat patients with follicular lymphoma, large-cell lymphomas, chronic lymphocytic leukemia and acute lymphoblastic leukemia.
Treats: Leukemia, B cells
For example, the CD19 molecule is expressed on more than 90% of B cell malignancies and on non-plasma B cells at all differentiation stages and has been successfully used to treat patients with follicular lymphoma, large-cell lymphomas, chronic lymphocytic leukemia and acute lymphoblastic leukemia.
Treats: Type 1 Diabetes, Autoimmune disease
The transfer of regulatory T cells has been used to treat Type 1 diabetes and others.
View the SourceReader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.